Rapid Micro Biosystems Inc (RPID)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $32.65M
Last updated: Nov 17, 2026 at 4:10 PM ET
Rapid Micro Biosystems Inc (RPID) Statistics
Rapid Micro Biosystems (RPID) has a market cap of $32.65M and an enterprise value of $37.11M. It kept -145.55% of revenue as net income over the last 12 months. Its share count is up 8.28% from a year earlier.
Total Valuation
Enterprise value is 13.63% above the market cap, as debt exceeds cash.
| Market Cap | $32.65M |
|---|---|
| Enterprise Value | $37.11M |
| Latest price (Nov 17, 2026) | $0.74 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.0x and 2.0x. Its year-end P/S ranged from 1.1x to 3.8x from 2021 to 2025.
| P/S Ratio | 1.0x |
|---|---|
| Forward P/S | 0.8x |
| P/B Ratio | 2.0x |
Price Statistics
The stock is down 82.50% over 52 weeks and trades 17.78% below its 50-day average.
| Beta (1Y) | 1.79 |
|---|---|
| 52-Week Change | -82.50% |
| 1-Month Change | -4.76% |
| 3-Month Change | -56.66% |
| 6-Month Change | -62.79% |
| 5-Year Change | -96.39% |
| Total Return (1Y) | -82.50% |
| Total Return (3Y CAGR) | -10.27% |
| Total Return (5Y CAGR) | -46.16% |
| Max Drawdown (1Y) | -86.75% |
| Max Drawdown (3Y) | -86.75% |
| Sharpe Ratio (1Y) | -2.23 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $0.90 |
| 200-Day Average | $2.02 |
| 52-Week Range | $0.58 to $4.94 |
| RSI (14 Days) | 44.6 |
| Average Volume (20 Days) | 1.15M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.55x current liabilities, and total debt is 1.08x shareholder equity.
| Current Ratio | 2.55x |
|---|---|
| Quick Ratio | 1.51x |
| Debt / Equity | 1.08x |
| Interest Coverage | -21.20x |
Returns and Efficiency
Return on invested capital is -135.11% over the last 12 months, against a 5-year average of -91.16%.
| Return on Equity (ROE) | -288.48% |
|---|---|
| Return on Assets (ROA) | -87.60% |
| Return on Invested Capital (ROIC) | -135.11% |
| Return on Capital Employed (ROCE) | -123.67% |
| ROE (5Y Average) | -63.78% |
| ROA (5Y Average) | -41.93% |
| ROIC (5Y Average) | -91.16% |
| Asset Turnover | 0.52x |
| Inventory Turnover | 1.83x |
| Receivables Turnover | 5.92x |
| Cash Conversion Cycle | 207 days |
Scores
RPID has an Altman Z-Score of -14.27, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -14.27 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $35.18M over the last 12 months is up 16.13% from the 12 months before.
| Revenue | $35.18M |
|---|---|
| Revenue Growth (YoY) | +16.13% |
| Gross Profit | $1.95M |
| Operating Income | -$49.76M |
| Pretax Income | -$51.13M |
| Net Income | -$51.20M |
| EBITDA | -$46.69M |
| EBIT | -$49.84M |
| Reported EPS (TTM) | -$1.08 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 30.37% of the $58.45M in total assets.
| Cash and Equivalents | $14.69M |
|---|---|
| Total Debt | $19.14M |
| Net Debt | $4.45M |
| Net Debt Per Share | $0.09 |
| Working Capital | $28.11M |
| Shareholder Equity | $17.75M |
| Book Value Per Share | $0.37 |
| Total Assets | $58.45M |
| Total Liabilities | $40.70M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $782.00K of capital spending, operating cash flow left -$40.84M of free cash flow.
| Operating Cash Flow | -$40.06M |
|---|---|
| Capital Expenditures | $782.00K |
| Free Cash Flow | -$40.84M |
| FCF Per Share | -$0.89 |
| Depreciation and Amortization | $3.15M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -141.45%.
| Gross Margin | 5.55% |
|---|---|
| Operating Margin | -141.45% |
| Pretax Margin | -145.34% |
| Net Margin | -145.55% |
| EBITDA Margin | -132.74% |
| EBIT Margin | -141.68% |
| FCF Margin | -116.10% |
| Gross Margin (5Y Average) | -20.96% |
Growth
Revenue grew 25.15% a year over 3 years.
| Revenue Growth (3Y CAGR) | +25.15% |
|---|---|
| Revenue Growth (5Y CAGR) | +15.88% |
| Book Value Per Share Growth (2Y CAGR) | -47.84% |
| Tangible Book Per Share Growth (2Y CAGR) | -47.84% |
Dividends and Yields
RPID does not pay a dividend. Its free cash flow yield is -114.65%.
| FCF Yield | -114.65% |
|---|---|
| Buyback Yield | -28.92% |
| Shareholder Yield | -28.92% |
Peer Position
Against 10 similar companies, RPID has the 8th highest P/S.
P/S RatioPeer median 2.6x
ROICPeer median -103.26%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.36%
| P/S Ratio | 1.0x vs 2.6x median |
|---|---|
| ROIC | -135.11% vs -103.26% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +16.13% vs +6.36% median |
Analyst Forecast
Consensus estimates put revenue growth at 16.58% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +16.58% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RPID
What is RPID's market cap?
Rapid Micro Biosystems has a market cap of $32.65M. Its enterprise value, which adds debt and subtracts cash, is $37.11M.
How many shares of RPID are outstanding?
Rapid Micro Biosystems has 48.35M shares outstanding. The count is up 8.28% from a year earlier.
Does RPID pay a dividend?
No. Rapid Micro Biosystems does not pay a dividend.
How much debt does RPID have?
Rapid Micro Biosystems has $19.14M of total debt and $14.69M of cash and equivalents, a net debt position of $4.45M.
RPID pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts